Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
Fludarabine and busulfan becomes standard conditioning regimen for adult patients with acute
myeloid leukemia (AML) or myelodysplasia syndrome (MDS). The overall relapse rate is 15~20%.
More recently, the investigators demonstrated that conditioning regimen with dual alkylating
agents consistent of fludarabine, busulfan and melphalan achieved a low incidence of relapse
(<10%). This multiple-center randomize study is aim to compare the transplantation outcome in
adult patients with AML/MDS undergoing allo-HSCT with conditioning regimen of Flu-Bu4 vs.
FLu-Bu-Mel.